Double Medical Technology Inc. (002901.SZ) has a MoatMap StockRank of 66/100 based on Quality (82/100), Value (34/100), and Momentum (35/100) factor scores. The current signal is BUY. Double Medical is a high-quality Chinese orthopedic medical device company, but it faces severe domestic headwinds from China's Volume-Based Procurement (VBP) program, which severely compresses margins. It lacks alignment with our macro themes and carries elevated geopolitical and regulatory risks.
Double Medical Technology Inc. is a leading Chinese medical device company specializing in the development and manufacture of orthopedic implants, including trauma, spine, and joint reconstruction systems. The company holds a strong market position in China's orthopedic sector, benefiting from government-led import substitution policies and centralized procurement programs. Its competitive moat is sustained by a comprehensive product portfolio, extensive clinical relationships, and cost-effective manufacturing.
| Price | $6.08 |
| Market Cap | $2.5B |
| P/E (TTM) | 25.59 |
| P/E (Forward) | 32.09 |
| Price/Book | 4.44 |
| Return on Equity | 19.2% |
| Return on Invested Capital | 18.2% |
| Debt/Equity | 9.34 |
| Gross Margin | 69.4% |
| Operating Margin | 29.6% |
| Revenue Growth | 16.6% |
| Dividend Yield | 1.2% |
| Free Cash Flow | $13M |
Double Medical Technology Inc. operates in the Medical Devices industry, part of the Healthcare sector (China).